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Introduction
Vagal nerve stimulation (VNS) emerged in the 1980s as a treatment alternative for pharmacoresistant epilepsy that is not amenable to resective surgery [1] . Having gained approval by the United States Food and Drug Administration (FDA) in 1997, this modality has become an established neuromodulatory treatment option for this group of patients [2] . Implantable pulse generator (IPG) models have evolved over time, with the latest being the first closed-loop VNS device, AspireSR 1 (Seizure Response).
Cardiac-based seizure detection (CBSD) uses ictal tachycardia as a surrogate marker for seizure prediction [3] [4] [5] [6] . The sudden tachycardia that is often associated with a seizure episode has triggered interest in CBSD and now the AspireSR 1 (model #106) has been demonstrated to have the ability to sense this ictal tachycardia as a proxy to an epileptic seizure and deliver a closed À loop electrical current to the vagus nerve [5] [6] [7] . This IPG may also be able to differentiate this ictal tachycardia from rise in heart rate due to other causes however this is yet to be proven [5] .
The traditionally held view is that one-third of implanted patients will have significant benefit of !50% seizure burden reduction, one-third of patients will have less meaningful benefit, and the final third will have little benefit. More recent large retrospective case series have reported that 8% become seizure free, approximately 20% will have >90% seizure reduction and approximately 70% have >50% reduction in seizure frequency [8] . We postulated that the AspireSR 1 would be better than previous VNS models at controlling seizures in patients with epilepsy who are considered to be pharmacoresistant. The aim of this study is to compare the efficacy of the AspireSR 1 at a large complex epilepsy and surgery center with preceding VNS battery models for battery replacements and to determine the response to AspireSR 1 for new implants. We performed a retrospective analysis of all VNS AspireSR 1 insertions and battery changes over a three-year period.
Methodology
We retrospectively reviewed the electronic records of adult patients who had VNS AspireSR 1 implanted by a single surgeon over the three-year period June 2014 through to June 2017 at the Queen Elizabeth Hospital Birmingham, United Kingdom. Our study was divided into two separate cohorts, the first being those patients who had AspireSR 1 implanted as their first VNS model ("new insertions cohort") and the second being those who had VNS battery changed from a previous model to AspireSR 1 ("battery change cohort"). Supplemental telephone interviews were employed by the surgical team to trace eight patients in the battery change cohort whose follow-up details were not available electronically.
Seizure burden estimates & outcome classification
Seizure burden data were estimated using seizure frequency and severity as reported by patients and caregivers. Each patient's response to VNS therapy was classified according to McHugh classification using a combination of each patient's interpretation or that of the clinician as documented in the electronic database or reported during telephone interviews. The McHugh classification is a VNS-specific seizure burden response considering seizure frequency and severity changes after IPG insertion [9] . It divides response into five categories.
Device programming and interrogation parameters
Device interrogation and programming information were retrieved from a combination of outpatient clinic notes, operative notes and the hospital's Motion VNS Therapy v11.0 programmer used in the operating theatre and Epilepsy Service outpatient department. The latter was done by matching either the patient allocation number or serial number of the implanted device. These identification data were available in the patients' electronic file or in the operating theatre records. Key for the new insertion cohort as the time of attaining normal stimulation mode current of 1.5miliamperes (1.5 mA) and thereby completing the ramping up phase À the process of increasing stimulation to optimal levels. In the battery change cohort, therapeutic AutoStim parameters is classified as being achieved when attaining any of the following:
i Two incremental increases in stimulation current ii Two incremental decreases in threshold heart rate detection iii No further adjustment in device parameters was warranted.
Where none of the above information was available, this period was assumed to be six weeks.
Comparison periods
The periods being considered in the analysis of the two cohorts are shown in Fig. 1 . In each case, for the periods after the insertion of a VNS, seizure burdens were recorded once therapeutic stimulation was achieved. For the new insertion cohort, the pre-VNS seizure burden was compared to the post-AspireSR 1 burden.
For the battery change cohort, three periods were used: pre-VNS, post-initial VNS and post-AspireSR 1 . Comparisons were made between the first and second periods, to assess the improvement resulting from the initial VNS, and between the second and third periods, to assess any subsequent improvement resulting from the AspireSR 1 . The changes in the estimated yearly seizure frequency were aligned to the McHugh classification of VNS outcomes [9] . Reported seizure frequencies were converted to a common denominator (i.e. seizures per year), prior to analysis. Where patients reported their seizure frequency as a range, the midpoint was used. Thus we extrapolated for those patients who were followed up for less than one year. The device programming parameters were used to derive the duty cycle at which each device was being operated, and comparisons were made between pre-and post-AspireSR 1 therapy, to assess if a change in duty cycle could have influenced the outcome in the cohort of patients who demonstrated significant benefit (!50% seizure burden reduction) after battery change to AspireSR 1 .
Theory & calculation
Estimated yearly seizure frequencies were found to follow skewed distributions, and so these were reported as medians with interquartile ranges (IQRs) and compared between periods using Wilcoxon's Signed-Rank Tests. In the battery change cohort, the post-initial VNS and post-AspireSR 1 improvements were then classified, based on the McHugh classification of VNS outcomes.
The resulting values were then compared, to assess whether those patients who expressed an improvement after their initial VNS insertion tended to report similar improvements after the battery was changed to AspireSR 1 .
All analyses were performed using IBM SPSS Statistics 22 (IBM Corp. Armonk, NY). Patients with missing data were excluded on a per-analysis basis. A p-value < 0.05 was deemed to be indicative of statistical significance throughout.
Surgical technique
All patients had a left cervical skin crease incision and the battery secured in a left anterior chest wall subcutaneous pouch, except for one patient who had an interscapular IPG placed. We did not find it necessary to extend the incision to accommodate the larger AspireSR 1 battery as Schneider had found when replacing a Demipulse 1 model [6] . For these battery change cases, we used the previous incision, and developed a more caudal subcutaneous pocket regardless of the battery model being replaced. A video record of our unit's surgical technique for new implant procedures is available for review at LivaNova Data on file (video upon request).
Results

Patient demographics
Our cohort consisted of 151 patients treated with AspireSR 1 VNS therapy over the three-year period. Three were excluded as lead revisions, leaving 77 new insertions and 71 battery changes.
By the end of follow up, 26 (34%) of the new insertion cohort were still undergoing ramping up, and nine (13%) of the battery change cohort were having their AutoStim parameters adjusted. After excluding these patients, a total of 113 were included in the study, made up of 51 new insertions and 62 battery changes. The study flowchart is reported in Fig. 2 .
For the 113 patients studied, the median age at initiation of Fig. 3 . A total of 59% (n = 30) of the cohort reported !50% reduction in seizure burden post-AspireSR 1 therapy. Of these, 21
(41% of the cohort) reported !80% reduction in seizure burden. Three patients (6% of the cohort) report having had no seizures in two, seven and 15 months after completing ramping up of VNS therapy. Among the poor responders in this cohort, eight patients (16%) at best had their seizures dampened or aborted with swiping of the magnet of whom five (10% of the cohort) reported no antiepileptic benefit from VNS therapy.
Outcomes in the AspireSR
1 battery change cohort
Prior to VNS therapy, the 62 patients in this cohort had a median of 336 seizures per year (IQR: 84-1680). Following initial VNS insertion, this decreased significantly (p < 0.001, Table 1 ) to a median of 90 per year (IQR: 12-672), with 53% (n = 33) of patients reporting !50% reduction in seizure burden.
When the battery was changed to the AspireSR 1 , patients reported a further significant reduction in seizure burden . These translate into 20% and 19% less work, respectively, by the AspireSR 1 compared to the replaced models, without losing the previous benefit gained from VNS therapy. The rationale for the duty cycle step down in the other two patients was unclear.
The remaining seven (16%) patients with significant benefit had the device duty cycle turned up, with a median increase of 33% (range: 21-100%) relative to that of their previous VNS. Five of these were in an attempt to further improve on seizure reduction; one was to facilitate further antiepileptic drug reduction and one successfully targeted benefit in hyperactivity and attention deficit.
A comparison of the improvements resulting from the two VNS therapies is reported in Table 2 . The improvement in McHugh classification associated with the AspireSR 1 was found to be significantly greater than that for a patient's previous VNS (p < 0.001), with 31% (n = 19) of patients seeing a greater response to the AspireSR 1 than their previous VNS. Of the seven patients who only had a magnet swipe benefit from their initial VNS, two (29%) reported improvements in seizure burden after changing the battery to AspireSR
1
. The swipe benefit was retained after the battery change for the remaining five patients.
Only one patient reported a smaller benefit with AspireSR 1 therapy, compared to their initial VNS. This 32 year-old woman who has Tuberous Sclerosis (TS) reported a 50-79% reduction in seizure burden after initial VNS, which was followed by <50% improvement after the battery change to the AspireSR 1 .
Interrogation of her device revealed extremely high impedance (>10 000 V) and that the device was delivering Output Current of only 0.5 mA, despite AutoStim being programmed at 1.125 mA. This high impedance suggested malfunctioning of the lead from a previous model that was originally placed in 1999 and she has been offered lead revision surgery. In addition, a single patient, a 21 year-old woman with severe Intellectual Disability (ID), reported no antiepileptic benefit from either initial VNS therapy, or after a battery change to AspireSR 1 , although she did maintain benefits to cognition and challenging behaviour attributed to VNS.
Procedural complications
Of the total 151 patients with AspireSR
1
, there were four cases (2.6%) of transient vocal cord paresis, all with complete resolution within 4-6 months and one case of lead migration (0.7%) suspected after a severe convulsive seizure soon after implant insertion requiring revision surgery. There were no reported cases of postoperative haemorrhage or surgical site infection in our cohort of patients. In the new insertions cohort, data were not available for two patients in the Post-AspireSR 1 period, hence these were excluded from the calculation of the medians and comparisons between the periods. In the battery change cohort, data were not available for one patient each for the pre-VNS and post-initial VNS periods, and for three patiens in the Post-AspireSR 1 period, hence these were excluded from the calculation of the medians and comparisons between the associated periods. p-Values are from Wilcoxon's tests where statistical significance is defined as p < 0.05 Fig. 3 . Seizure burden response to VNS in the two cohorts.
Discussion
VNS was introduced in the 198Os and was not approved by the FDA until a decade later [1, 2] . Now three decades on, VNS is the main neuromodulatory treatment option for medically refractory epilepsy not amenable to resective surgery.
The reporting of outcome measures in epilepsy is of paramount importance for any treatment modality and this holds true for vagal nerve therapy. There have been a number of publications comparing the VNS outcomes among different patient populations [8] [9] [10] [11] [12] . We compared our experience with AspireSR 1 not only to our pre-AspireSR 1 experience, but also with the existing literature [8, 9, 13, 14] . Our population consisted of a mixture of seizure types and we did not differentiate outcome based on gender, seizure type or laterality as Chen and colleagues have previously done nor did we differentiate based on age or concomitant co-morbidities [4] .
We found that battery change to AspireSR 1 resulted in significant reduction in seizure burden (!50% reduction) in 71% of cases, which is greater than reported in the available literature for both adult and pediatric VNS population to date. This is evident earlier with AspireSR 1 treatment as, at a mean follow up of 13 months, 59% of our new insertion cohort had already reported this significant degree of benefit (see Fig. 4 ).
Patient with deteriorating seizure control following AspireSR
therapy
We identified one patient with deteriorating seizure control following VNS battery change to AspireSR 1 . This patient had a lead malfunction from a previous IPG model and made an informed choice not to undertake lead revision surgery after being counseled about the risks of the operation, which included up to 22% risk of Table 2 Hamilton-Soryal Actuarial 
AspireSR 1 battery change in a non-responder
VNS battery change to AspireSR 1 was offered to one patient who previously had no antiepileptic benefit from VNS therapy. This patient who had severe Intellectual Disability (ID) reported significant benefit attributed to VNS for improved cognition and behaviour. She maintained this degree of the widely accepted benefit of VNS therapy in this community of patients but continued to have no antiepileptic benefit after the battery was changed to the AspireSR 1 [18, 19] .
Patient counseling-modification of the 'rule of thirds'
We routinely categorize our VNS implanted patients' outcomes according to the McHugh classification system. In light of our findings, the information presented to patients may need to be modified as we report that, with battery change to AspireSR 1 , approximately one-third (29%) of patients will have <50% benefit, one-third (35%) will have 50-79% benefit and another one-third (35%) will have even !80% benefit (See Fig. 3 ). The proportion of patients who did not benefit was found to be negligible (<2%).
Although this is a retrospective study with small sample size, our findings suggest that patients who reported 1-49% reduction in seizure burden with a device prior to AspireSR 1 should be considered for a battery change, as 52% of this sub-cohort (n = 11) achieved clinically significant additional benefit (See Table 2 ). This is an important finding but requires replication by other studies. In our discussion with patients, we abbreviate the automatic stimulation mode as 'automatic magnet swipe.' The inherent ability of the AspireSR 1 to detect the ictal tachycardia associated with four-fifths of all seizures is a significant advancement, as delivering an on-demand electrical stimulation can dampen or abort a seizure without any active effort by the patient or care giver [5] . For example, one of our patients improved from McHugh class IV to McHugh class III, for which we believe that AutoStim of the AspireSR 1 is primarily responsible. This is supported by the almost 20% Total On Time of the device being accounted for by AutoStim compared to <1% by the magnet in this index patient. In our study population, there was no increase in duty cycle in 83% of those who attained significant benefit (!50% seizure burden reduction) after battery change to AspireSR 1 . This improvement in seizure control is likely due to the AutoStim feature inherent to the VNS AspireSR 1 model, as there was no increase in duty cycle.
Limitations & generalizability
Our study was a retrospective analysis and we reported patients' and carers' interpretation of their response to VNS therapy rather than by prospectively collected seizure diaries or a formal quality of life assessment tool. This retrospective seizure reporting was therefore a potential source of recall bias. Similarly, the lack of blinding and randomization could have resulted in selection bias as patients who were more likely to have had benefit from VNS therapy were offered treatment with AspireSR J .
Although we compared seizure burden at different periods, we did not compare our CBSD period with another group that is being treated concurrently with VNS other than CBSD IPG. Whilst we have not looked at concurrent medication changes, the VNS is used as an adjunct usually with no changes to medications within the first 12 months rather than as a replacement for medications.
Strengths of our study include the careful selection of patients for VNS therapy through a MDT process to exclude patients with misdiagnosis and the fact that a consistent approach to VNS programming was applied. The actuarial table presented for our battery change cohort may become applicable to individual patients as a predictor of potential response to CBSD IPG such as the AspireSR J , as a function of their response to previous VNS model(s).
Conclusion
In our study, the 59% response rate for new implants at the 50% improvement in seizure frequency threshold were better than reported in most previously published studies, although in line with outcomes reported by Elliot et al. (2011) . In addition, patients experience meaningful improvement sooner with this cardiacbased seizure detection VNS therapy. VNS therapy with CBSD IPG (AspireSR 1 ) achieved a greater seizure control benefit over a mean of 13 months duration of therapy than reported figures achieved after longer treatment duration of up to five years. In addition, 71% of our study population reported an additional improvement in seizure control at the 50% threshold for improved seizure frequency following battery change from previous IPG models to the AspireSR J IPG. The majority (74%) did not require a change to the duty cycle. An additional 18% of those who underwent a battery change experienced !50% seizure reduction response over a mean of 21 months of AspireSR 1 therapy.
The closed À loop cycle is not dependent on patient or caregiver compliance as it is an automated system. This device improved the number of good responders, while reducing the number of poor responders to VNS therapy. The 'rule of thirds' when applied to patient counseling could be revised accordingly.
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